generation run 2026-05-12
63 min completedmodel pipeline-v5plan not recordedrun/4ae8e3c3…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- safety_data_unverified
- safety_data_unverified
- safety_data_unverified
- sparse_evidence
- sparse_evidence
- sparse_evidence
- sparse_evidence
- contradictory_sources
- contradictory_sources
- contradictory_sources
- structural_inference
- structural_inference
- structural_inference
- structural_inference
- structural_inference
- structural_inference
- structural_inference
Reproduce
- inputs
- 33 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
23 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | OpenAlex | theacrine purine alkaloid pharmacology | 15 | 4 | High-citation landmark papers on theacrine health effects and biosynthesis |
| 2 | WebSearch | theacrine legal status scheduling FDA WADA banned substance 2026 | 10 | 0 | Legal status confirmation - unscheduled in major jurisdictions |
| 3 | WebSearch | theacrine insufflated snorted intranasal route of administration | 10 | 0 | Investigating brief's claim of insufflated ROA - not supported by evidence |
| 4 | PubChem | theacrine | 1 | 1 | Primary chemical identity verification |
| 5 | PubMed | theacrine adenosine receptor dopamine caffeine | 1 | 1 | Foundational pharmacological mechanism study |
| 6 | PubMed | theacrine energy supplement exercise fatigue | 3 | 0 | Duplicate results already captured |
| 7 | WebSearch | theacrine 1,3,7,9-tetramethyluric acid first isolation discovery history | 10 | 1 | Historical discovery context |
| 8 | PubMed | theacrine (all results) | 25 | 6 | Adverse effects data (Vieira-Cavalcante 2025), sleep effects (Gardiner 2024), inflammation (Li 2024), cancer (Ko 2019), egaming (Tartar 2021), ergogenic (Jovanov 2025) |
| 9 | ClinicalTrials.gov | theacrine | 3 | 3 | All completed trials; relevant to clinical data on theacrine |
| 10 | PubMed | theacrine Camellia kucha biosynthesis | 10 | 4 | Biosynthesis history and broader pharmacological studies |
| 11 | PubMed | theacrine human clinical study cognitive performance | 7 | 7 | Human RCT data on cognitive performance, safety, energy/mood effects |
| 12 | PubMed | theacrine pharmacokinetics metabolism half-life | 1 | 2 | Critical PK data - contradicts 5-day half-life in brief |
| 13 | WebSearch | theacrine SMILES CAS number | 10 | 0 | Verified CAS number and SMILES for chemical identity section |
| 14 | PubMed | theacrine pharmacology mechanism action | 1 | 1 | Neuroprotective pharmacology |
| 15 | PubMed | PMID 12009315 - Zheng 2002 biosynthesis | 1 | 1 | Foundational history/biosynthesis paper |
| 16 | WebSearch | theacrine TeaCrine supplement first market Compound Solutions patent history | 10 | 1 | Commercial history context for substance entry |
| 17 | PubMed | theacrine NAD3 stem cell supplement aging | 2 | 2 | Aging/sirtuin pathway effects of theacrine |
| 18 | PubMed | theacrine cancer breast tumor metastasis | 1 | 1 | Relevant to anti-cancer properties section |
| 19 | multiple · absence | insufflated ROA claim in brief vs published literature | 0 | 0 | Critical flag: ROA error in seed data |
| 20 | PubMed | PMID 29727630 - NAFLD acylcarnitine | 1 | 1 | Hepatoprotective/metabolic effects |
| 21 | PubMed | PMID 41323841 - gastric emptying pharmacokinetics | 1 | 1 | Critical PK data contradicting 5-day half-life claim |
| 22 | multiple | half-life discrepancy: brief says 5 days vs literature 21 hours | 2 | 2 | Critical discrepancy flag for generation agent |
| 23 | PubMed cross-reference | adverse effects safety summary across all studies | 6 | 3 | Safety profile compilation |
78 claims by section — every cited sentence, checked against its source
safety22 · 21 ok
Ziegenfuss and colleagues confirmed hemodynamic safety at 200 mg in acute dosing, with no changes in resting heart rate, gas exchange, or oxygen consumptionsupported
Part 2 (RCT, 200mg): No resting HR, gas exchange, or hemodynamic changes. 19390211.2016.1178678
He and colleagues found no hemodynamic differences between theacrine alone, caffeine alone, and the combination at pharmacokinetic study doses.supported
No hemodynamic effects. Enhanced oral bioavailability hypothesized mechanism. jcr.2017.0006
The most rigorous safety assessment comes from Taylor and colleagues' 8-week RCT (n = 60): oral theacrine at 200 mg/day and 300 mg/day produced no clinically significant changes in heart rate, blood pressure, lipid profiles, complete blood count, or liver, kidney, and immune biomarkerssupported
8-week RCT (n=60): 200-300 mg/day TeaCrine®. All clinical safety markers within normal limits. s12970-016-0113-3
Vieira-Cavalcante and colleagues found that 6 mg/kg theacrine (~420 mg for a 70 kg individual) significantly elevated resting systolic and diastolic blood pressure in trained cyclists (n = 19)supported
6 mg/kg increased resting systolic and diastolic BP. apnm-2024-0442
Stoke and colleagues found no significant heart rate or blood pressure effects at 3, 6, or 9 mg/kg, but observed elevated salivary cortisol at 120–180 minutes post-dose in theacrine conditions.supported
No significant effects on HR, BP. Increased salivary cortisol at 120-180 min vs placebo. apnm-2025-0380
Li and colleagues demonstrated decreased ALT/AST, reduced inflammatory cytokines, and reversed histological liver damage in restraint-stressed micesupported
Oral theacrine (10-30 mg/kg, 7 days) decreased plasma ALT/AST, reduced hepatic inflammatory cytokines (IL-1β, TNF-α, IL-6, IFN-γ), reversed histological damage. jf400982c
Wang and colleagues found protection against non-alcoholic fatty liver disease in an animal modelsupported
Theacrine protects against NAFLD by targeting acylcarnitine metabolism disorder. j.metabol.2018.04.011
Stoke and colleagues documented elevated salivary cortisol at doses of 3–9 mg/kg (approximately 210–630 mg for a 70 kg individual) at 120–180 minutes post-administrationsupported
RCT (n=19), 3/6/9 mg/kg doses: increased salivary cortisol at 120-180 min vs placebo. apnm-2025-0380
Anxiety was not elevated relative to placebo in the 8-week safety trialsupported
No group × time interactions on energy, focus, anxiety, POMS. s12970-016-0113-3
Tartar and colleagues found that a caffeine-theacrine-methylliberine combination increased alertness without increasing anxiety, whereas caffeine alone increased self-reported anxiety.supported
Caffeine alone increased anxiety but CDT did not. cureus.20534
At higher doses (≥6 mg/kg), side-effect reports include subjective distress symptoms — dizziness, head pressure, lack of disposition — that may have a psychological componentsupported
Reported side effects: GI discomfort, perceived tachycardia, dizziness, headache, head pressure, hand tremor, lack of disposition. apnm-2024-0442
Taylor and colleagues' 8-week RCT detected no tachyphylaxis: energy, focus, concentration, and motivation scores remained stable across the full study duration at both 200 mg and 300 mgsupported
No habituation or tachyphylaxis detected. No group × time interactions on energy, focus, anxiety, POMS. s12970-016-0113-3
Feduccia and colleagues independently found no locomotor sensitization or tolerance in chronically dosed ratssupported
No locomotor sensitization or tolerance after chronic exposure. j.pbb.2012.04.014
Caffeine co-administration increases theacrine's plasma exposure (Cmax and AUC) through enhanced presystemic bioavailabilitysupported
Caffeine co-admin increases theacrine Cmax and AUC without altering half-life. Enhanced oral bioavailability hypothesized mechanism. jcr.2017.0006
Cardiovascular parameters are not additively elevated at typical combination doses.supported
No hemodynamic effects. jcr.2017.0006
Cardiovascular parameters are not additively elevated at typical combination doses.supported
No HR or BP changes. nu7115484
Claim in safety — inconclusiveinconclusiveworking →
The 21-hour half-life necessitates a minimum washout period of approximately 4 days before adenosine-dependent procedures.supported
Theacrine elimination t1/2 = 21.00 ± 7.55 hours. j.ijpx.2025.100442
Cardiovascular conditions (relative). Blood pressure elevation at doses ≥6 mg/kg and perception of tachycardia at supplementation doses suggest caution in individuals with uncontrolled hypertension, cardiac arrhythmias, or other cardiovascular diseasesupported
6 mg/kg increased resting systolic and diastolic BP. Reported side effects: perceived tachycardia. apnm-2024-0442
Anxiety disorders (relative). Although theacrine appears less anxiogenic than caffeine at typical doses, its stimulant mechanism (adenosine antagonism, dopaminergic facilitation) warrants caution in individuals with panic disorder or generalized anxiety disorder, particularly at higher doses.supported
Caffeine alone increased anxiety but CDT did not. cureus.20534
HPA axis disorders (relative). The cortisol-elevating effect at doses ≥3 mg/kg suggests caution in individuals with Cushing's syndrome, adrenal insufficiency under glucocorticoid replacement, or other HPA axis pathology.supported
Increased salivary cortisol at 120-180 min vs placebo. apnm-2025-0380
Discontinuation before such procedures is required, with the 21-hour half-life dictating a minimum washout period of approximately 4 days (4–5 half-lives).supported
Theacrine elimination t1/2 = 21.00 ± 7.55 hours. j.ijpx.2025.100442
clinical-evidence9 · 9 ok
The foundational safety study is Taylor and colleagues' 8-week, double-blind, randomized controlled trial (n = 60) evaluating TeaCrine® at 200 mg/day and 300 mg/day against placebosupported
8-week RCT (n=60): 200-300 mg/day TeaCrine®. All clinical safety markers within normal limits. No habituation or tachyphylaxis detected. s12970-016-0113-3
Ziegenfuss and colleagues confirmed hemodynamic safety at 200 mg in a two-part acute study, finding no changes in resting heart rate, gas exchange, or hemodynamic parameters.supported
Part 2 (RCT, 200mg): No resting HR, gas exchange, or hemodynamic changes. 19390211.2016.1178678
Gardiner and colleagues examined dose-response (100 mg and 400 mg) and consumption timing effects on cognitive performance and sleep in a within-subjects designsupported
100mg and 400mg theacrine: no significant sleep disruption. Within 8h of bedtime improved next-morning PVT lapses (400mg). s41598-024-79046-2
Stoke and colleagues administered higher doses (3, 6, and 9 mg/kg) and found no significant cognitive performance improvements at any dose, but observed elevated salivary cortisol at 120–180 minutes post-dose.supported
RCT (n=19), 3/6/9 mg/kg doses: increased salivary cortisol at 120-180 min vs placebo. No significant effects on cognitive performance. apnm-2025-0380
Vieira-Cavalcante and colleagues administered 3 and 6 mg/kg theacrine to trained cyclists (n = 19) and found no improvement in 4 km time trial performancesupported
RCT (n=19): 3 and 6 mg/kg theacrine did not improve cycling TT. apnm-2024-0442
Kuhman and colleagues (n = 20) evaluated theacrine combined with caffeine against placebo and caffeine alone, finding higher subjective attentiveness, alertness, focus, and energy with the combination, alongside reduced lethargy and grogginesssupported
RCT (n=20): TheaTrim (theacrine+caffeine) vs caffeine 150mg vs placebo. Subjective improvements in attentiveness, alertness, focus, and energy. nu7115484
Lints and colleagues demonstrated that a caffeine-theacrine combination improved cognitive performance in military personnel under physically fatiguing conditions, suggesting synergistic cognitive effects under stress.supported
Military tactical personnel: caffeine+theacrine combination improved cognitive performance under physical fatigue. 15502783.2025.2536146
Bello and colleagues studied TeaCrine® combined with caffeine in high-level soccer players, reporting endurance and cognitive benefits during simulated match conditions.supported
High-level athletes: TeaCrine® alone improved time-to-exhaustion 27-38%; combination with caffeine provided greater cognitive benefits than either independently. s12970-019-0287-6
Cesareo and colleagues found no ergogenic effect of TeaCrine® on muscular strength, endurance, or power in resistance-trained men.supported
RCT (n=12): TeaCrine 300mg did not improve 1RM strength, RTF, or power vs placebo. s12970-019-0316-5
pharmacology9 · 6 ok
In Long Evans rats, pre-treatment with theacrine significantly attenuated the motor depression induced by co-administration of the A₁ agonist CPA and the A₂A agonist CGS-21680, establishing functional antagonism at both receptor subtypessupported
Theacrine significantly enhances locomotor activity via adenosinergic (A1/A2A antagonism) and dopaminergic (D1/D2) mechanisms in rats. j.pbb.2012.04.014
Claim in pharmacology — inconclusiveinconclusiveworking →
At low doses in rodents (3 mg/kg intragastric), theacrine acts as a sedative/hypnotic agent — increasing NREM sleep duration, shortening wake time, and augmenting pentobarbital-induced sleep through what appears to be adenosine agonism-like activitysupported
Theacrine 3mg/kg (i.g.) enhanced pentobarbital sleep, increased NREM, no effect on REM. A1 and A2A receptor antagonists reversed sleep effect. Increased adenosine in hippocampus. j.neulet.2017.08.063
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Half-life. The elimination half-life in humans is 21.00 ± 7.55 hours (salivary pharmacokinetics), substantially longer than caffeine's 3–6 hourssupported
Theacrine elimination t1/2 = 21.00 ± 7.55 hours. j.ijpx.2025.100442
He and colleagues conducted a crossover pharmacokinetic study (n = 8) demonstrating that co-administration of caffeine (150 mg) with theacrine (125 mg) significantly increased theacrine's Cmax and AUC without altering its elimination half-lifesupported
Crossover PK study (n=8): theacrine alone shows consistent PK; caffeine co-admin increases theacrine Cmax and AUC without altering half-life. jcr.2017.0006
Tartar and colleagues genotyped participants for the CYP1A2*1F allele in a caffeine-theacrine-methylliberine combination study; allele status did not moderate outcomes, though this single observation does not resolve the metabolic pathway question.supported
CYP1A2*1F allele status did not moderate effects. cureus.20534
The caffeine-mediated enhancement of theacrine exposure suggests presystemic losses are pharmacologically relevant but modifiable.supported
Caffeine co-admin increases theacrine Cmax and AUC without altering half-life. Enhanced oral bioavailability hypothesized mechanism. jcr.2017.0006
summary8 · 8 ok
Individual response varies with caffeine co-consumption, which increases theacrine's systemic exposure through enhanced oral bioavailability.supported
Caffeine co-admin increases theacrine Cmax and AUC without altering half-life. No hemodynamic effects. Enhanced oral bioavailability hypothesized mechanism. jcr.2017.0006
Distinguished from caffeine by C8 oxidation and N9 methylation of the purine scaffold, theacrine produces wakefulness and cognitive stimulation at oral doses of 100–300 mg with a notably prolonged elimination half-life of approximately 21 hours.partially supported
Identified theacrine synthase CkTcS from Kucha with N9-methyltransferase activity; C8 oxidation precedes N9-methylation. s41467-020-15324-7
Distinguished from caffeine by C8 oxidation and N9 methylation of the purine scaffold, theacrine produces wakefulness and cognitive stimulation at oral doses of 100–300 mg with a notably prolonged elimination half-life of approximately 21 hours.partially supported
Theacrine elimination t1/2 = 21.00 ± 7.55 hours. j.ijpx.2025.100442
First reported as a minor tea constituent in 1937, theacrine remained pharmacologically uncharacterized until Feduccia and colleagues established its adenosine and dopamine receptor involvement in 2012supported
Theacrine significantly enhances locomotor activity via adenosinergic (A1/A2A antagonism) and dopaminergic (D1/D2) mechanisms in rats. j.pbb.2012.04.014
The compound's primary research significance lies in its non-habituating profile: an 8-week randomized controlled trial detected no tolerance to subjective energy, focus, or motivation effects at doses up to 300 mg/day — a property that distinguishes it from caffeine and most other adenosine-targeting stimulants.supported
8-week RCT (n=60): 200-300 mg/day TeaCrine®. No habituation or tachyphylaxis detected. No group × time interactions on energy, focus, anxiety, POMS. s12970-016-0113-3
Theacrine's stimulant effects are mediated by adenosine A₁ and A₂A receptor antagonism and downstream dopaminergic activation, demonstrated through pharmacological blocking studies and nucleus accumbens infusion experiments in rodentssupported
Theacrine significantly enhances locomotor activity via adenosinergic (A1/A2A antagonism) and dopaminergic (D1/D2) mechanisms in rats. Nucleus accumbens implicated. j.pbb.2012.04.014
Oral theacrine at 200–300 mg/day produces no clinically significant changes in heart rate, blood pressure, or hematological markers over eight weeks of continuous usesupported
8-week RCT (n=60): 200-300 mg/day TeaCrine®. All clinical safety markers within normal limits. s12970-016-0113-3
Doses at or above 6 mg/kg (~420 mg for a 70 kg individual) elevate resting blood pressure and produce gastrointestinal discomfort, tachycardia perception, and tremor in some individualssupported
6 mg/kg increased resting systolic and diastolic BP. Reported side effects: GI discomfort, perceived tachycardia, dizziness, headache, head pressure, hand tremor, lack of disposition. apnm-2024-0442
neuroscience7 · 6 ok
Claim in neuroscience — inconclusiveinconclusiveworking →
However, the absence of locomotor sensitization or tolerance in chronic rodent exposure suggests that theacrine's dopaminergic modulation does not produce the progressive neuroadaptation characteristic of stimulants with high abuse liability.supported
No locomotor sensitization or tolerance after chronic exposure. j.pbb.2012.04.014
PDE4/cAMP/CREB/BDNF/TrkB pathway. In chronic unpredictable mild stress mouse models, theacrine promotes adult hippocampal neurogenesis and counters stress-induced serotonergic dysregulation through this signaling cascadesupported
Mechanism: PDE4/cAMP/CREB/BDNF/TrkB pathway; promotes hippocampal neurogenesis. acs.jafc.1c01514
SIRT3/FOXO3a/Parkin pathway. Theacrine protects dopaminergic neurons in Parkinson's disease models via SIRT3 activation, and the same pathway mediates anti-inflammatory effects in psoriasis modelspartially supported
Animal study: theacrine protects dopaminergic neurons in PD model via SIRT3 activation; anti-oxidative neuroprotection mechanism. j.phymed.2020.153281
Separately, a theacrine-containing supplement increased SIRT1 mRNA, global sirtuin activity, and NAD⁺ levels approximately 2-fold in C2C12 muscle cells in vitro.supported
NAD3 (theacrine-based) increased Sirt1 mRNA at 3h, global sirtuin activity at 3 and 24h, NAD+ levels elevated ~2-fold at 24h. nu12123727
Nrf2/Rac1 pathway. In ischemic stroke models (middle cerebral artery occlusion in rats) and human endothelial cells, theacrine activates the Nrf2 antioxidant pathway and inhibits Rac1, reducing oxidative stress, apoptosis, and vascular injury.supported
MCAO rat model and HUVECs: theacrine reduces oxidative stress, apoptosis, and vascular injury. Inhibits Rac1 and activates Nrf2/ARE pathway. j.intimp.2025.115951
Gut-brain axis. Theacrine-containing Kucha black tea modulated gut microbiota composition and increased brain serotonin, dopamine, and BDNF while decreasing pro-inflammatory cytokines IL-6 and TNF-α in chronic stress depression models.supported
Modified gut microbiota; increased 5-HT, DA, BDNF; decreased IL-6, TNF-α. j.foodres.2024.115306
chemistry5 · 3 ok
This distinguishes theacrine from the methylxanthine class (which includes caffeine, theobromine, and theophylline) by the presence of a C8 carbonyl rather than C8-H, representing a single oxidation step beyond the xanthine scaffold.supported
C8 oxidation precedes N9-methylation. s41467-020-15324-7
Theacrine is the direct biosynthetic product of caffeine (1,3,7-trimethylxanthine) via C8 oxidation to 1,3,7-trimethyluric acid followed by N9 methylationsupported
Theacrine synthesized from adenosine via caffeine in a three-step pathway; 1,3,7-methyluric acid is intermediate. pmid:12009315
Claim in chemistry — inconclusiveinconclusiveworking →
Theacrine occurs at pharmacologically meaningful concentrations in the leaves of Camellia assamica var. kucha (Kucha tea), where young leaves accumulate approximately 2.8% by dry weight — replacing caffeine as the dominant purine alkaloidsupported
Endogenous levels: ~2.8% dry weight in young kucha leaves. pmid:12009315
Claim in chemistry — not_supportednot supportedworking →
comparative-pharmacology5 · 5 ok
The absence of tolerance over 8 weeks is theacrine's most pharmacologically distinctive property relative to caffeinesupported
No habituation or tachyphylaxis detected. s12970-016-0113-3
Tartar and colleagues found that caffeine alone increased self-reported anxiety while a caffeine-theacrine-methylliberine combination increased alertness without anxiety, suggesting theacrine may buffer caffeine's anxiogenic effects — though the presence of methylliberine confounds direct attribution.supported
Caffeine alone increased anxiety but CDT did not. cureus.20534
The pharmacokinetic interaction is well characterized: caffeine enhances theacrine's oral bioavailability (Cmax and AUC) without altering its elimination ratesupported
Caffeine co-admin increases theacrine Cmax and AUC without altering half-life. Enhanced oral bioavailability hypothesized mechanism. jcr.2017.0006
Pharmacodynamically, the combination appears synergistic for cognitive outcomes under fatiguing conditions and during sustained athletic performancesupported
Combination with caffeine provided greater cognitive benefits than either independently. s12970-019-0287-6
Cardiovascular parameters are not additively elevated at typical supplementation doses.supported
No hemodynamic effects. jcr.2017.0006
history4 · 3 ok
Young Kucha leaves contain approximately 2.8% theacrine by dry weight.supported
Endogenous levels: ~2.8% dry weight in young kucha leaves. pmid:12009315
Claim in history — inconclusiveinconclusiveworking →
Zhu and colleagues cloned the caffeine oxidase gene CsCDH in 2025, establishing it as the rate-limiting enzyme in theacrine productionsupported
CsCDH is rate-limiting enzyme in theacrine synthesis pathway. j.ijbiomac.2025.140429
Wu and colleagues identified a second theacrine synthase, CsTcS2, regulated by the CsTINY-CsWRKY33 transcription factor module.supported
Identified CsTcS2 as novel theacrine synthase; CsTINY-CsWRKY33 transcription factor module regulates CsTcS2. pbi.70665
effects-overview3 · 3 ok
Caffeine co-consumption meaningfully modulates intensity via pharmacokinetic enhancement of theacrine's systemic exposuresupported
Caffeine co-admin increases theacrine Cmax and AUC without altering half-life. Enhanced oral bioavailability hypothesized mechanism. jcr.2017.0006
Theacrine occupies a position between caffeine and prescription wakefulness-promoting agents in the stimulant landscape — more sustained than caffeine (21-hour vs 3–6-hour half-life) with a cleaner anxiety-sparing profile, but without the potent wakefulness-promoting efficacy of modafinilsupported
Theacrine elimination t1/2 = 21.00 ± 7.55 hours. j.ijpx.2025.100442
Its closest experiential analog is caffeine at moderate doses, minus the tolerance development and with reduced sleep disruption.supported
100mg and 400mg theacrine: no significant sleep disruption (minor non-significant effects at 400mg). s41598-024-79046-2
pharmacokinetic-detail3 · 1 ok
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Tartar and colleagues genotyped participants for the CYP1A2*1F polymorphism — associated with variable caffeine metabolism rates — in a study of the caffeine-theacrine-methylliberine combinationsupported
CYP1A2*1F allele status did not moderate effects. cureus.20534
receptor-pharmacology3 · 3 ok
The low-dose sedative/hypnotic effect observed in rodents (3 mg/kg intragastric) suggests possible partial agonist activity or dose-dependent switching between agonism and antagonism at adenosine receptors — a pharmacological profile that would be unusual among xanthine-derived compounds and warrants formal characterization.supported
A1 and A2A receptor antagonists reversed sleep effect. Increased adenosine in hippocampus. j.neulet.2017.08.063
Theacrine-stimulated locomotion is blocked by both D₁ (SCH23390) and D₂ (eticlopride) receptor antagonists, and bilateral infusion into the nucleus accumbens (10–20 µg) produces dose-dependent locomotor activationsupported
Theacrine significantly enhances locomotor activity via adenosinergic (A1/A2A antagonism) and dopaminergic (D1/D2) mechanisms in rats. Nucleus accumbens implicated. j.pbb.2012.04.014
Functional antagonism at adenosine A₁ and A₂A receptors is established through behavioral pharmacology: theacrine pre-treatment attenuates motor depression induced by the A₁-selective agonist CPA and the A₂A-selective agonist CGS-21680 in ratssupported
Theacrine significantly enhances locomotor activity via adenosinergic (A1/A2A antagonism) and dopaminergic (D1/D2) mechanisms in rats. j.pbb.2012.04.014